Featured Article Academic Journal Main Category: Cancer / Oncology Also Included In: Immune System / Vaccines;Stem Cell Research Article Date: 28 Mar 2012 – 2:00 PDT
email to a friend printer friendly opinions
Current Article Ratings:
4 (3 votes)
4 (1 votes)
Senior author Dr Irving Weissman, professor of pathology at Stanford, and colleagues, write about their success in treating bladder, brain, breast, colon, liver, ovarian, and prostate cancer tumors in this week’s online ahead of print issue of the Proceedings of the National Academy of Sciences.
They say the antibody blocks a protein known as CD47, that sends “don’t eat me” signals that cancer cells use to stop macrophages and other cells of the immune system from gobbling them up.
Anti-CD47 is the first antibody treatment to work against a variety of human solid tumors. The investigators said they are now eager to get started with phase 1 and phase 2 clinical trials in humans within the next two years.
The treatment also significantly reduced the ability of the tumors to spread (metastasize) to other parts of the mice’s bodies, and in some cases, the animals appeared to be “cured”.
Weissman, who directs the Institute of Stem Cell Biology and Regenerative Medicine and the Ludwig Center for Cancer Stem Cell Research and Medicine, both at Stanford, told the press their findings show “conclusively” that CD47 is a “a legitimate and promising target for human cancer therapy”:
Antibody Shrinks Tumors Of Seven Cancers